P
Pamela G. Coxson
Researcher at University of California, San Francisco
Publications - 64
Citations - 5872
Pamela G. Coxson is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Population & Cost effectiveness. The author has an hindex of 30, co-authored 60 publications receiving 5306 citations. Previous affiliations of Pamela G. Coxson include San Francisco General Hospital & University of California.
Papers
More filters
Journal ArticleDOI
Projected Effect of Dietary Salt Reductions on Future Cardiovascular Disease
Kirsten Bibbins-Domingo,Glenn M. Chertow,Pamela G. Coxson,Andrew E. Moran,James Lightwood,Mark J. Pletcher,Lee Goldman +6 more
TL;DR: In this article, the authors used the Coronary Heart Disease (CHD) Policy Model to quantify the benefits of potentially achievable, population-wide reductions in dietary salt of up to 3 g per day (1200 mg of sodium per day).
Journal ArticleDOI
Adolescent overweight and future adult coronary heart disease.
TL;DR: Ex extrapolation from current data suggests that adolescent overweight will increase rates of CHD among future young and middle-aged adults, resulting in substantial morbidity and mortality.
Journal ArticleDOI
Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model.
Milton C. Weinstein,Pamela G. Coxson,Lawrence W. Williams,T M Pass,William B. Stason,Lee Goldman +5 more
TL;DR: B baseline projections indicate that the aging of the population, and especially the maturation of the post-World War II baby-boom generation, would increase CHD prevalence and annual incidence, mortality, and costs by about 40-50 per cent by the year 2010.
Journal ArticleDOI
Future Cardiovascular Disease in China Markov Model and Risk Factor Scenario Projections From the Coronary Heart Disease Policy Model–China
Andrew E. Moran,Dongfeng Gu,Dong Zhao,Pamela G. Coxson,Y. Claire Wang,Chung-Shiuan Chen,Jing Liu,Jun Cheng,Kirsten Bibbins-Domingo,Yu-Ming Shen,Jiang He,Lee Goldman +11 more
TL;DR: Aging and population growth will increase cardiovascular disease by more than a half over the coming 20 years, and projected unfavorable trends in blood pressure, total cholesterol, diabetes, and body mass index may accelerate the epidemic.
Journal ArticleDOI
Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.
Jean-Michel Gaspoz,Pamela G. Coxson,Paula A. Goldman,Lawrence W. Williams,Karen M. Kuntz,M. G. Myriam Hunink,M. G. Myriam Hunink,Lee Goldman +7 more
TL;DR: Increased prescription of aspirin for secondary prevention of coronary heart disease is attractive from a cost-effectiveness perspective, unless its use is restricted to patients who are ineligible for aspirin.